However, more specific EZH2 inhibitors including EPZ005687 and EPZ011989 are now available and have proved very successful at killing lymphoma cells, these new drugs may show therapeutic promise in EZH2 high HCC patients [92], [93]. Here, EZH2 is linked to hepatocellular carcinoma.